Manufacturing of recombinant therapeutic proteins in microbial systems

被引：118

作者：

Novartis Biopharmaceutical Operations, Sandoz GmbH, Kundl, Austria ^{[1
]}

机构：

[1] Novartis Biopharmaceutical Operations, Sandoz GmbH, Kundl

来源：

Biotechnol. J. | 2006年 / 2卷 / 164-186期

关键词：

Downstream processing; Fermentation; In-process control; Microbial expression systems; Product characterization;

D O I：

10.1002/biot.200500051

中图分类号：

学科分类号：

摘要：

Recombinant therapeutic proteins have gained enormous importance for clinical applications. The first recombinant products have been produced in E. coli more than 20 years ago. Although with the advent of antibody-based therapeutics mammalian expression systems have experienced a major boost, microbial expression systems continue to be widely used in industry. Their intrinsic advantages, such as rapid growth, high yields and ease of manipulation, make them the premier choice for expression of non-glycosylated peptides and proteins. Innovative product classes such as antibody fragments or alternative binding molecules will further expand the use of microbial systems. Even more, novel, engineered production hosts and integrated technology platforms hold enormous potential for future applications. This review summarizes current applications and trends for development, production and analytical characterization of recombinant therapeutic proteins in microbial systems. © 2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

引用

页码：164 / 186

页数：22

共 173 条

[1]

Walsh G., Biopharmaceutical benchmarks - 2003, Nat. Biotechnol., 21, 8, pp. 865-870, (2003)

[2]

Walsh G., Current status of biopharmaceuticals: Approved products and trends in approvals, Modern Biopharmaceuticals, pp. 1-34, (2005)

[3]

Reichert J.M., Paquette C., Therapeutic recombinant proteins: Trends in US approvals 1982 to 2002, Curr. Opin. Mol. Ther., 5, 2, pp. 139-147, (2003)

[4]

Baneyx F., Recombinant protein expression in Escherichia coli, Curr. Opin. Biotechnol., 10, 5, pp. 411-421, (1999)

[5]

Swartz J.R., Advances in Escherichia coli production of therapeutic proteins, Curr. Opin. Biotechnol., 12, 2, pp. 195-201, (2001)

[6]

Andersen D.C., Krummen L., Recombinant protein expression for therapeutic applications, Curr. Opin. Biotechnol., 13, pp. 117-123, (2002)

[7]

Jana S., Deb J.K., Strategies for efficient production of heterologous proteins in Escherichia coli, Appl. Microbiol. Biotechnol., 67, 3, pp. 289-298, (2005)

[8]

Zhou L., Zhang K., Wanner B.L., Chromosomal expression of foreign and native genes from regulatable promoters in Escherichia coli, Methods Mol. Biol., 267, pp. 123-134, (2004)

[9]

Sorensen H.P., Mortensen K.K., Advanced genetic strategies for recombinant protein expression in Escherichia coli, J. Biotechnol., 115, pp. 113-128, (2005)

[10]

Grabherr R., Bayer K., Impact of targeted vector design on ColE1 plasmid replication, Trends Biotechnol, 20, 6, pp. 257-260, (2002)

← 1 2 3 4 5 6 7 8 9 10 →